Printer Friendly

ICN PHARMACEUTICALS EXPECTS RECORD FIRST QUARTER SALES AND EARNINGS

ICN PHARMACEUTICALS EXPECTS RECORD FIRST QUARTER SALES AND EARNINGS
 COSTA MESA, Calif., April 23 /PRNewswire/ -- Milan Panic, chairman and chief executive officer of ICN Pharmaceuticals Inc. (NYSE: ICN), today told shareholders at its annual meeting that first quarter sales are anticipated to be approximately $140 million.
 Panic also said that net income per share is expected to be at least 45 cents.
 ICN sales and income benefited from a strong performance by SPI Pharmaceuticals Inc., its marketing subsidiary, and its new Eastern European venture, ICN Galenika.
 Full first quarter results will be released shortly, Panic said.
 ICN Pharmaceuticals Inc. headquartered in Costa Mesa, is a worldwide health care company that manufactures, markets and distributes a wide range of prescription, nonprescription pharmaceuticals, biotechnology research products and medical diagnostics worldwide.
 -0- 4/23/92
 /CONTACT: Paul Knopick of ICN Pharmaceuticals, 714-545-0100, ext. 2465/
 (ICN) CO: ICN Pharmaceuticals Inc. ST: California IN: MTC SU: ERP


KJ -- LA033 -- 2029 04/23/92 15:11 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 23, 1992
Words:161
Previous Article:BOSE DESIGNS EXTRA-LIGHT, HIGHLY EFFICIENT MUSIC SYSTEM FOR STATE-OF-THE-ART ELECTRIC CAR
Next Article:PHARMAKINETICS LABORATORIES, INC., ANNOUNCES SALE OF GERMAN SUBSIDIARY


Related Articles
SPI PHARMACEUTICALS EXPECTS RECORD FIRST QUARTER SALES AND EARNINGS
ICN PHARMACEUTICALS REPORTS RECORD FIRST QUARTER SALES AND EARNINGS; LONG-TERM LIABILITIES REDUCED BY $40 MILLION
ICN PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS
ICN PHARMACEUTICALS REPORTS PROFIT IN THE FIRST QUARTER; DECONSOLIDATES SPI
ICN REPORTS RECORD NET INCOME AND EPS IN FIRST QUARTER 1995; SALES UP 83 PERCENT
ICN PHARMACEUTICALS REPORTS RECORD SALES, NET INCOME AND EARNINGS PER SHARE IN THIRD QUARTER
ICN PHARMACEUTICALS CONTINUES TO REDUCE DEBT - ANNOUNCES REDEMPTION OF THE LAST $13.697 MILLION OF ITS 12 7/8% SINKING FUND DEBENTURES
ICN Pharmaceuticals Declares Third Quarter Dividend
ICN Reports Record Third Quarter and Nine Months Sales, Net Income and Earnings Per Share

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters